Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30481

Type
Article
Copyright
Restricted access
Embargo date
2028-08-30
Collections
Share

Statistics
Metadata
Show full item record

ONCE-DAILY ATAZANAVIR/RITONAVIR VERSUS TWICE-DAILY LOPINAVIR/RITONAVIR, EACH IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE, FOR MANAGEMENT OF ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS: 48 WEEK EFFICACY AND SAFETY RESULTS OF THE CASTLE STUDY
Molina, Jean-Michel et al. | Date Issued: 2008
Author
Molina, Jean-Michel
Andrade-Villanueva, Jaime
Echevarria, Juan
Chetchotisakd, Ploenchan
Corral, Jorge
David, Neal
Moyle, Graeme
Mancini, Marco
Percival, Lisa
Yang, Rong
Thiry, Alexandra
McGrath, Donnie
CASTLE Study Team
Affilliation
Saint-Louis Hospital. Department of Infectious Diseases. Paris./ University of Paris-Diderot, Paris, France.
Hospital Civil de Guadalajara. Guadalajara, Mexico.
Hospital Nacional Cayetano Heredia. Lima, Peru.
Khonkaen University. Department of Medicine. Khonkaen, Thailand.
Hospital Interzonal Gral De Agudos Oscar Alende. Buenos Aires, Argentina.
Brooklyn Medical Centre. Western Cape, South Africa.
Chelsea and Westminster Hospital. London, UK.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Bristol-Myers Squibb. Research and Development. Wallingford, CT, USA.
Abstract
Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable lipid profile and less gastrointestinal toxicity, in treatment-experienced HIV-1-infected patients. We compared these two combinations directly in treatment-naive patients.
Keywords
HIV
Atazanavir Sulfate
Lopinavir
Ritonavir
Drug Administration
 
Publisher
Elsevier
Citation
MOLINA, J. M. et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, v. 372, n. 9639, p. 646-655, 2008.
DOI
10.1016/S0140-6736(08)61081-8
ISSN
0140-6736
Notes
Presente no CASTLE Study Team: Beatriz Grinsztejn (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil).